FOXM1 overexpression is associated with cisplatin resistance in non-small cell lung cancer and mediates sensitivity to cisplatin in A549 cells via the JNK/mitochondrial pathway

Neoplasma

Volumn 62, Issue 1, 2015, Pages 61-71

  Liu, Y ^a   Chen, X ^a   Gu, Y ^a   Zhu, L ^a   Qian, Y ^a   Pei, D ^a   Zhang, W ^a   Shu, Y ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

A549; Cisplatin; Drug resistance; FoxM1; JNK mitochondrial pathway; Non small cell lung cancer

Indexed keywords

CISPLATIN; SMALL INTERFERING RNA; STRESS ACTIVATED PROTEIN KINASE;

A549 CELL LINE; ADULT; AGED; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CHEMOSENSITIVITY; CONTROLLED STUDY; CYTOTOXICITY ASSAY; DRUG SENSITIVITY; FEMALE; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PROTEIN DEPLETION; PROTEIN EXPRESSION; RNA INTERFERENCE; WESTERN BLOTTING;

EID: 84933521582     PISSN: 00282685     EISSN: 13384317     Source Type: Journal    
DOI: 10.4149/neo_2015_008     Document Type: Article

References (46)

1. JEMAL A, SIEGEL R, WARD E, MURRAY T, XU J et al. Cancer statistics, 2007. CA Cancer J Clin 2007; 57: 43-66. http://dx.doi.Org/10.3322/canjclin.57.1.43
2. JEMAL A, MURRAY T, WARD E, SAMUELS A, TIWARI RC et al. Cancer statistics, 2005. CA Cancer J Clin 2005; 55: 10-30. http://dx.doi.org/10.3322/caniclin.55.1.10
3. MOLINA JR, YANG P, CASSIVISD, SCHILD SE, ADJEI AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008; 83: 584-594. http://dx.doi.org/10.1016/S0025-6196(11)60735-0
4. KELLAND L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 2007; 7:573-584. http://dx.doi.org/10.1038/nrc.2167
5. STEWART DJ. Mechanisms of resistance to cisplatin and carboplatin. Crit Rev Oncol Hematol 2007; 63: 12-31. http://dx.doi.org/10.1016/j.critrevonc.2007.02.001
6. MADUREIRA PA, VARSHOCHI R, CONSTANTINIDOU D, FRANCIS RE, COOMBES RC et al. The Forkhead box M1 protein regulates the transcription of the estrogen receptor alpha in breast cancer cells. J Biol Chem 2006; 281: 25167-25176. http://dx.doi.org/10.1074/jbc.M603906200
7. WIERSTRA I, ALVES J. FOXMlc and Spl transactivate the P1 and P2 promoters of human c-myc synergistically. Biochem Biophys Res Commun 2007; 352: 61-68. http://dx.doi.org/10.1016/i.bbrc.2006.10.151
8. WONSEY DR, FOLLETTIE MT. Loss of the forkhead transcription factor FoxM1 causes centrosome amplification and mitotic catastrophe. Cancer Res 2005; 65: 5181-5189. http://dx.doi.org/10.1158/0008-5472.CAN-04-4059
9. PETROVIC V, COSTA RH, LAU LF, RAYCHAUDHURI P, TYNER AL. FoxM1 regulates growth factor-induced expression of kinase-interacting stathmin (KIS) to promote cell cycle progression. J Biol Chem 2008; 283: 453-460. http://dx.doi.org/10.1074/jbc.M705792200
10. PARK HJ, COSTA RH, LAU LF, TYNER AL, RAYCHAUDHURI P. Anaphase-promoting complex/cyclosome-CDH1-mediated proteolysis of the forkhead box Ml transcription factor is critical for regulated entry into S phase. Mol Cell Biol 2008; 28: 5162-5171. http://dx.doi.org/10.1128/MCB.00387-08
11. LAOUKILI J, KOOISTRA MR, BRAS A, KAUW J, KERKHOVEN RM et al. FoxM1 is required for execution of the mitotic programme and chromosome stability. Nat Cell Biol 2005; 7: 126-136. http://dx.doi.org/10.1038/ncb1217
12. HUANG C, QIU Z, WANG L, PENG Z, JIA Z et al. A novel FoxM 1 -caveolin signaling pathway promotes pancreatic cancer invasion and metastasis. Cancer Res 2012; 72: 655-665. http://dx.doi.org/10.1158/0008-5472.CAN-11-3102
13. XIA JT, WANG H, LIANG LJ, PENG BG, WU ZF et al. Overexpression of FOXM 1 Is Associated With Poor Prognosis and Clinicopathologic Stage of Pancreatic Ductal Adenocarcinoma. Pancreas 2012; 41:629-635. http://dx.doi.org/10.1097/MPA.0b013e31823bcef2
14. KIM IM, ACKERSON T, RAMAKRISHNA S, TRETIAKOVA M, WANG IC et al. The Forkhead Box m 1 transcription factor stimulates the proliferation of tumor cells during development of lung cancer. Cancer Res 2006; 66:2153-2161. http://dx.doi,org/10.1158/0008-5472.CAN-05-3003
15. BEKTAS N, HAAF A, VEECK J, WILD PJ, LÜSCHER-FIRZLAFF J et al. Tight correlation between expression of the Forkhead transcription factor FOXM1 and HER2 in human breast cancer. BMC Cancer 2008; 8:42. http://dx.doi,org/10.1186/1471-2407-8-42
16. CHU XY, ZHU ZM, CHEN LB, WANG JH, SU QS et al. FOXM1 expression correlates with tumor invasion and a poor prognosis of colorectal cancer. Acta Histochem 2012; 114: 755-762. http://dx.doi.Org/10.1016/Lacthis.2012.01.002
17. BERGAMASCHI A, CHRISTENSEN BL, KATZENEL-LENBOGEN BS. Reversal of endocrine resistance in breast cancer: interrelationships among 14-3-3zeta, FOXM1, and a gene signature associated with mitosis. Breast Cancer Res 2011; 13: R70. http://dx.doi.org/10.1186/bcr2913
18. REN S, ZHOU S, ZHANG L, XU J, LV M et al. High-level mRNA of excision repair cross-complementation group 1 gene is associated with poor outcome of platinuin-based doublet chemotherapy of advanced nonsmall cell lung cancer patients. Cancer Invest 2010; 28: 1078-1083. http://dx.doLorg/10.3109/07357901003735659
19. MILLOUR J, DE OLANO N, HORIMOTO Y, MONTEIRO LJ, LANGER JK. ATM and p53 regulate FOXM1 expression via E2F in breast cancer epirubicin treatment and resistance. Mol Cancer Ther 2011; 10: 1046-1058. http://dx.doLorg/10.1158/1535-7163.MCT-11-0024
20. KWOK JM, PECK B, MONTEIRO LJ, SCHWENEN HD, MILLOUR J. FOXM 1 confers acquired cisplatin resistance in breast cancer cells. Mol Cancer Res 2010; 8: 24-34. http://dx.doi.org/10.1158/1541-7786.MCR-09-0432
21. MARINTCHEV A, ROBERTSON A, DIMITRIADIS EK, PRASAD R, WILSON SH et al. Domain specific interaction in the XRCC1-DNA polymerase beta complex. Nucleic Acids Res 2000; 28: 2049-2059. http://dx.doi.org/10.1093/nar/28.10.2049
22. KARRAN P. DNA double strand break repair in mammalian cells. Curr Opin Genet Dev 2000; 10: 144-150. http://dx.doi.org/10.1016/S0959-437X(00)00069-l
23. TUTT A, BERTWISTLE D, VALENTINE J, GABRIEL A, SWIFT S et al. Mutation in Brca2 stimulates error-pronĉ homology-directed repair of DNA double-strand breaks occurring between repeated sequences. EMBO J 2001; 20: 4704-4716. http://dx.doi.org/10.1093/emboi/20.17.4704
24. YUAN SS, LEE SY, CHEN G, SONG M, TOMLINSON GE et al. BRCA2 is required for ionizing radiation-induced assembly of Rad51 complex in vivo. Cancer Res 1999; 59: 3547-3551.
25. TAN Y, RAYCHAUDHURI R COSTA RH. Chk2 mediates stabilization of the FoxM1 transcription factor to stimulate expression of DNA repair genes. Mol Cell Biol 2007; 27: 1007-1016. http://dx.doi.org/10.1128/MCB.01068-06
26. PARK YY, JUNG SY, JENNINGS N, RODRIGUEZ-AGUAYO C, PENG G et al. FOXM1 mediates Dox resistance in breast cancer by enhancing DNA repair. Carcinogenesis 2012; 33: 1843-1853. http://dx.doi.org/10.1093/carcin/bgs167
27. CARR JR, PARK HJ, WANG Z, KIEFER MM, RAYCHAUDHURI P. FoxM1 mediates resistance to herceptin and paclitaxel. Cancer Res 2010; 70: 5054-5063. http://dx.doi.orp/10.1158/0008-5472.CAN-10-0545
28. XU N, ZHANG X, WANG X, GE HY, WANG XY et al. FoxM1 mediated resistance to gefitinib in non-smallcell lung cancer cells. Acta Pharmacol Sin 2012; 33: 675-681. http://dx.doi.org/10.1038/aps.2011.188
29. WANG G, REED E, LI QQ. Molecular basis of cellular response to cisplatin chemotherapy in non-small cell lung cancer (Review). Oncol Rep 2004; 12: 955-965.
30. ASHKENAZI A, DIXIT VM. Death receptors: signaling and modulation. Science 1998; 281: 1305-1308. http://dx.doi.org/10.1126/science.281.5381.1305
31. COSTA RH. FoxM1 dances with mitosis. Nat Cell Biol 2005; 7: 108-110. http://dx.doi.org/10.1038/ncb02Q5-108
32. WANG IC, CHEN YJ, HUGHES DE, ACKERSON T, MAJOR ML et al. FoxM1 regulates transcription of JNK1 to promote the G1/S transition and tumor cell invasiveness. J Biol Chem 2008; 283: 20770-20778. http://dx.doi.org/10.1074/jbc.M709892200
33. BURKE JG, RW GW, CONHYEA D, MCCORMACK D, DOWLING FE et al. Human nucleus pulposis can respond to a pro-inflammatory stimulus. Spine (Phila Pa 1976) 2003; 28: 2685-2693. http://dx.doi.org/10.1097/01.BRS.0000103341.45133.F3
34. CHANG L, KARIN M. Mammalian MAP kinase signalling cascades. Nature 2001; 410: 37-40. http://dx.doi.org/10.1038/35065000
35. FENG DY, ZHENG H, TAN Y, CHENG RX. Effect of phosphorylation of MAPK and Stat3 and expression of c-fos and c-jun proteins on hepatocarcinogenesis and their clinical significance. World J Gastroenterol 2001; 7: 33-36.
36. RAGGATT LJ, EVDOKIOU A, FINDLAY DM. Sustained activation of Erk1/2 MAPK and cell growth suppression by the insert-negative, but not the insert-positive isoform of the human calcitonin receptor. J Endocrinol 2000; 167: 93-105. http://dx.doi.org/10.1677/joe.0.1670093
37. WADA T, PENNINGER JM. Mitogen-activated protein kinases in apoptosis regulation. Oncogene 2004; 23: 2838-2849. http://dx.doi.orp/10.1038/sj.onc.1207556
38. JOHNSON GL, LAPADAT R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 2002; 298: 1911-1912. http://dx.doi.org/10.1126/science.1072682
39. MA RY, TONG TH, CHEUNG AM, TANG AC, LEUNG WY et al. Raf/MEK/MAPK signaling stimulates the nuclear translocation and transactivating activity of FOXM1c. J Cell Sci 2005; 118: 795-806. http://dx.doi.org/10.1242/ics.01657
40. BEHREN A, MÜHLEN S, ACUNA SANHUEZA GA, SCHWAGER C, PLINKERT PK et al. Phenotype-assisted transcriptome analysis identifies FOXM1 downstream from Ras-MKK3-p38 to regulate in vitro cellular invasion. Oncogene 2010; 29: 1519-1530. http://dx.doi.org/10.1038/onc.2009.436
41. CHATTOPADHYAY S, MACHADO-PINILLA R, MANGUAN-GARCIA C, BELDA-INIESTA C, MORATILLA C et al. MKP1/CL100 controls tumor growth and sensitivity to cisplatin in non-small-cell lung cancer. Oncogene 2006; 25: 3335-3345. http://dx.doi.org/10.1038/sj.onc.1209364
42. WANG LY.TU Z. Lung tumor diagnosis and subtype discovery by gene expression profiling. Conf Proc IEEE Eng Med Biol Soc 2006; 1: 5868-5871.
43. ULUKAYA E, PIRIANOV G, KURT MA, WOOD EJ, MEHMET H. Fenretinide induces cytochrome c release, caspase 9 activation and apoptosis in the absence of mitochondrial membrane depolarisation. Cell Death Differ 2003; 10: 856-859. http://dx.doi.org/10.1038/si.cdd.4401242
44. YATA K, LLOYD J, MASLEN S, BLEUYARD JY, SKEHEL M et al. Plk1 and CK2 act in concert to regulate Rad51 during DNA double strand break repair. Mol Cell 2012; 45: 371-383. http://dx.doi.org/10.1016/i.molcel.2011.12.028
45. BENOIT DS, HENRY SM, SHUBIN AD, HOFFMAN AS, STAYTON PS. pH-rcsponsive polymeric sirna carriers sensitize multidrug resistant ovarian cancer cells to doxorubicin via knockdown of polo-like kinase 1. Mol Pharm 2010; 7: 442-455. http://dx.doi.orp/10.1021/mp9002255
46. JIMENO A, RUBIO-VIQUEIRA B, RAJESHKUMAR NV, CHAN A, SOLOMON A et al. A fine-needle aspirate-based vulnerability assay identifies polo-like kinase 1 as a mediator of gemcitabine resistance in pancreatic cancer. Mol Cancer Ther 2010;9:311-318. http://dx.doi.Org/10.l158/1535-7163.MCT-09-0693